ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference

CEO Richard Adcock used a presentation at the Citizens Life Sciences Conference to outline the company’s commercial progress ...
Cure Today

Anktiva Plus BCG Resubmitted to FDA for Papillary Bladder Cancer

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS with or without papillary tumors. FDA interactions centered on updated ...
Targeted Oncology

NCCN Expands Recommendation for Nadofaragene in BCG-Unresponsive NMIBC

NCCN upgraded support to category 2A for BCG-unresponsive high-grade papillary Ta/T1 without CIS, while maintaining category 2A for CIS ± Ta/T1, broadening guideline-backed use beyond prior consensus.

ImmunityBio (IBRX) Announces NCCN Update Clinical Practice Guidelines to Include ANKTIVA for Papillary-Only NMIBC

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best NASDAQ stocks under $30 to buy. On March 17, ImmunityBio announced that the National Comprehensive Cancer Network/NCCN updated its 2026 Clinical ...
Seeking Alpha

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary ...

ANKTIVA was approved by the FDA in 2024 with BCG for the treatment of BCG unresponsive NMIBC with Papillary tumors with CIS (Cohort A). In the same clinical trial (QUILT-3.032) long term results of ...
MarketWatch

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA(R) in BCG-Unresponsive Papillary Bladder Cancer

The MarketWatch News Department was not involved in the creation of this content. -- Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for ...
Targeted Oncology

CMS Issues J-code for Gemcitabine Intravesical System in NMIBC

The Centers for Medicare & Medicaid Services has issued a permanent billing and reimbursement J-code, J9183, for the ...
Nature

Ciliated Muconodular Papillary Tumors And Related Pulmonary Lesions

Ciliated muconodular papillary tumors (CMPTs) are rare, peripheral pulmonary lesions that have garnered increasing attention due to their unique histological and molecular characteristics. Typically ...
Nasdaq

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Medscape

Long-term Follow up Results of Intraductal Papillary Mucinous Tumors of Pancreas

Of the 67 cases, 27 cases (40.3%) were classified as the main duct type IPMT, 35 cases (52.2%) as the branch duct type IPMT, and five cases (7.5%) as the mixed duct type IPMT. There were 12 adenomas ...
Yahoo Finance

NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. NCCN has added ImmunityBio's ANKTIVA to its Clinical ...